A Review of Immunotherapy in Non-Small-Cell Lung Cancer

被引：5

作者：

Capella, Mariana Pilon ^{[1
]}

Pang, Steph A. ^{[1
]}

Magalhaes, Marcos A. ^{[2
]}

Esfahani, Khashayar ^{[1
,3
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada

[2] Hosp Beneficencia Portuguesa Sao Paulo, Dept Oncol, BR-01451010 Sao Paulo, Brazil

[3] McGill Univ, St Marys Hosp, Dept Oncol, Montreal, PQ H3T 1M5, Canada

来源：

CURRENT ONCOLOGY | 2024年 / 31卷 / 06期

关键词：

immunotherapy; non-small-cell lung cancer; squamous cell lung cancer; PD-1; CTLA-4; SPECIFIED FINAL ANALYSIS; BRAIN METASTASES; PLUS CHEMOTHERAPY; ADVERSE EVENTS; OPEN-LABEL; PHASE-III; PD-1/PD-L1; INHIBITORS; CLINICAL-OUTCOMES; PEMBROLIZUMAB; NSCLC;

D O I：

10.3390/curroncol31060258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer immunotherapy in the form of immune checkpoint inhibitors has led to a dramatic increase in the survival of patients with lung cancer across all stages. Over the past decade, the field has experienced rapid maturation; however, several challenges continue to complicate patient management. This review aims to highlight the data that led to this dramatic shift in practice as well as to focus on key challenges. These include determining the optimal therapy duration, managing frail patients or those with brain metastases, addressing the challenges posed by immune-related adverse events, and defining the various patterns of clinical and radiological responses to immunotherapy.

引用

页码：3495 / 3512

页数：18

共 93 条

[31] Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].

Goldberg, Sarah B. ;

Gettinger, Scott N. ;

Mahajan, Amit ;

Chiang, Anne C. ;

Herbst, Roy S. ;

Sznol, Mario ;

Tsiouris, Apostolos John ;

Cohen, Justine ;

Vortmeyer, Alexander ;

Jilaveanu, Lucia ;

Yu, James ;

Hegde, Upendra ;

Speaker, Stephanie ;

Madura, Matthew ;

Ralabate, Amanda ;

Rivera, Angel ;

Rowen, Elin ;

Gerrish, Heather ;

Yao, Xiaopan ;

Chiang, Veronica ;

Kluger, Harriet M. .

LANCET ONCOLOGY, 2016, 17 (07) :976-983

[32] A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study [J].

Gomes, F. ;

Lorigan, P. ;

Woolley, S. ;

Foden, P. ;

Burns, K. ;

Yorke, J. ;

Blackhall, F. .

ESMO OPEN, 2021, 6 (01)

[33] Understanding immunosenescence to improve responses to vaccines [J].

Goronzy, Joerg J. ;

Weyand, Cornelia M. .

NATURE IMMUNOLOGY, 2013, 14 (05) :428-436

[34] Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors [J].

Hendriks, Lizza E. L. ;

Henon, Clemence ;

Auclin, Edouard ;

Mezquita, Laura ;

Ferrara, Roberto ;

Audigier-Valette, Clarisse ;

Mazieres, Julien ;

Lefebvre, Corentin ;

Rabeau, Audrey ;

Le Moulec, Sylvestre ;

Cousin, Sophie ;

Duchemann, Boris ;

le Pechoux, Cecile ;

Botticella, Angela ;

Ammari, Samy ;

Gazzah, Anas ;

Caramella, Caroline ;

Adam, Julien ;

Lechapt, Emmanuele ;

Planchard, David ;

De Ruysscher, Dirk ;

Dingemans, Anne-Marie ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1244-1254

[35] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[36] Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer [J].

Heymach, John V. ;

Harpole, David ;

Mitsudomi, Tetsuya ;

Taube, Janis M. ;

Galffy, Gabriella ;

Hochmair, Maximilian ;

Winder, Thomas ;

Zukov, Ruslan ;

Garbaos, Gabriel ;

Gao, Shugeng ;

Kuroda, Hiroaki ;

Ostoros, Gyula ;

Tran, Tho V. ;

You, Jian ;

Lee, Kang-Yun ;

Antonuzzo, Lorenzo ;

Papai-Szekely, Zsolt ;

Akamatsu, Hiroaki ;

Biswas, Bivas ;

Spira, Alexander ;

Crawford, Jeffrey ;

Le, Ha T. ;

Aperghis, Mike ;

Doherty, Gary J. ;

Mann, Helen ;

Fouad, Tamer M. ;

Reck, Martin .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (18) :1672-1684

[37] Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J].

Horn, Leora ;

Spigel, David R. ;

Vokes, Everett E. ;

Holgado, Esther ;

Ready, Neal ;

Steins, Martin ;

Poddubskaya, Elena ;

Borghaei, Hossein ;

Felip, Enriqueta ;

Paz-Ares, Luis ;

Pluzanski, Adam ;

Reckamp, Karen L. ;

Burgio, Marco A. ;

Kohlhaeeufl, Martin ;

Waterhouse, David ;

Barlesi, Fabrice ;

Antonia, Scott ;

Arrieta, Oscar ;

Fayette, Jerome ;

Crino, Lucio ;

Rizvi, Naiyer ;

Reck, Martin ;

Hellmann, Matthew D. ;

Geese, William J. ;

Li, Ang ;

Blackwood-Chirchir, Anne ;

Healey, Diane ;

Brahmer, Julie ;

Eberhardt, Wilfried E. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) :3924-+

[38] Association between immune-related adverse event timing and treatment outcomes [J].

Hsiehchen, David ;

Naqash, Abdul Rafeh ;

Espinoza, Magdalena ;

Von Itzstein, Mitchell S. ;

Cortellini, Alessio ;

Ricciuti, Biagio ;

Owen, Dwight H. ;

Laharwal, Mehak ;

Toi, Yukihiro ;

Burke, Michael ;

Xie, Yang ;

Gerber, David E. .

ONCOIMMUNOLOGY, 2022, 11 (01)

[39] Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy [J].

Hwang, William L. ;

Niemierko, Andrzej ;

Hwang, Katie L. ;

Hubbeling, Harper ;

Schapira, Emily ;

Gainor, Justin F. ;

Keane, Florence K. .

JAMA ONCOLOGY, 2018, 4 (02) :253-255

[40]

International Agency for Research on Cancer, 2020, GLOBOCAN Lung Cancer Facts Sheet 2020.

← 1 2 3 4 5 6 7 8 9 10 →